

Curriculum Vitae

Sandhya Vasan, M.D.

A. General Information

Address for mail sent from USA: USAMC-AFRIMS; APO, AP 96546
Address for mail sent from outside USA: 315/6 Rajvithi Road; Bangkok, 10400, Thailand
Tel: +66-85-980-2499
Email: sandhya.vasan@afirms.org
Citizenship USA
MD Licensure New York MD-223859

B. Education

- 1988 -1992 Massachusetts Institute of Technology
S.B. in Mechanical Engineering, concentration in biomedical sciences.
Undergraduate Thesis: Endoscopic surgery: An assessment of laparoscopic and arthroscopic technique and instrumentation.
- 1992 -1997 Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology
Doctor of Medicine
MD Research Thesis: Lack of effect of galanin on LH, FSH and free alpha subunit secretion from perfused male rat anterior pituitary cells.

C. Postgraduate Training

- 1997 - 1998 Intern, Department of Pediatrics
Johns Hopkins Hospital, Baltimore, MD
- 1998 - 2000 Resident, Department of Pediatrics
Johns Hopkins Hospital, Baltimore, MD
- 2000 - 2001 Henry Luce Foundation Scholar
Communicable Disease Centre, Singapore
National University of Singapore Medical School, Singapore
- 2003 Johns Hopkins School of Public Health
Course: *Clinical Vaccine Trials: Planning and Implementation*

D. Academic Appointments

- 2002 - 2004 Clinical Scholar
Aaron Diamond AIDS Research Center,
Rockefeller University
New York, NY, USA
- 2004 – 2010 Instructor in Clinical Investigation
Aaron Diamond AIDS Research Center,
Rockefeller University
New York, NY, USA

2010 – 2011 Aaron Diamond Assistant Professor at the Rockefeller University
Aaron Diamond AIDS Research Center
New York, NY, USA

2011 – Present Clinical Trial Physician
United States Military HIV Research Program
Armed Forces Research Institute of Medical Sciences
Bangkok, Thailand

E. Hospital Appointments

2002 – 2011 Associate Attending Physician
Rockefeller University Hospital
The Rockefeller University
New York, NY, USA

F. Certification

1997 – Present Basic Life Support
1997 – 2000 Pediatric Advanced Life Support
1997 – 2000 Neonatal Advanced Life Support
2000 – 2007 Board Certification in Pediatrics
2002 – 2009 Advanced Cardiac Life Support
2002 – Present Human Subjects Training Education
2002 – Present DEA Certification
2003 Clinical Vaccine Trials and Good Clinical Practice Certification

G. Honors and Awards

1988 - 1992 Dow Jones National Merit Scholar
1991 - 1992 Sterling Winthrop Research Fellow in Health Sciences and Technology
1992 Wunsch Foundation Award for Excellence in Mechanical Engineering
Thesis
2002 - 2001 Henry Luce Foundation Scholar
2003 Fellow/Student Graduate Travel Grant Recipient – 11th Conference on
Retroviral and Opportunistic Infections
2003 - 2006 NIH Loan Repayment Award Recipient
2009 Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery
Young and Early Career Investigator

H. Professional Memberships and Committees

1991 - 1992 Member, Pi Tau Sigma – National Mechanical Engineering Honor Fraternity
1991 - 1992 Member, Tau Beta Pi – National Engineering Honor Fraternity
1997 – Present Member, American Academy of Pediatrics
2003 – Present Manuscript Reviewer, Journal of AIDS
2003 – Present Pediatric Consultant, Rockefeller University Institutional Review Board
2007 – Present Member, Pediatrics Oversight Committee of the National Clinical Translational
Science Award
2008 – Present Member, Advisory Committee on Clinical and Translational Science, Rockefeller
University

I. Laboratory Research

2006 – Present Aaron Diamond AIDS Research Center, New York (Ongoing Collaboration)

- Designing and conducting pre-clinical and clinical studies to determine the ability of a novel glycolipid compound to act as a vaccine adjuvant in humans

2002-2011 Aaron Diamond AIDS Research Center / Rockefeller University, New York

- Evaluated the safety and tolerability of in vivo electroporation in healthy human volunteers, and its capacity to enhance immunogenicity to DNA vaccines
- Developed studies to assess the effect of a novel monoclonal antibody directed at the D2 domain of the CD4 receptor (ibalizumab) to prevent SIV challenge after intravenous or intrarectal challenge in rhesus macaques.
- Developed multi-parametric immunomonitoring assays to quantify and qualify establishment of T cell memory in humans and mice
- Investigated the role of antiretroviral therapy on NKT cell quantity and function
- Researched gutless adenoviral vectors for HIV-1 vaccine development

Laboratory Techniques: Multiparametric Flow Cytometry
ELISA, ELISPOT, and radioimmunoassay
Cell & tissue culture and perfusion
PCR & Gel Electrophoresis
DNA Extraction, Transfection, and Amplification
RNA Extraction and Gene Array Expression Analysis

J. Clinical Research

1. 2002 – 2011 Aaron Diamond AIDS Research Center/ Rockefeller University: Clinical development of candidate HIV-1 vaccines with novel delivery systems (in vivo electroporation)

Pre-clinical responsibilities included preclinical development and immunogenicity assessments, design of pre-clinical GMP animal studies, pre-IND interactions with US FDA and support of IND filings, clinical protocol design, and SOP design for clinical sample acquisition and processing.

Clinical responsibilities included volunteer recruitment, filing and obtaining institutional IRB approval, interaction with clinical research pharmacist and nurse coordinator for vaccine shipment, storage, and preparation, clinical assessment of local and systemic reactogenicity and documentation and characterization of adverse events, coordination of clinical and specimen management, interactions with trial Data Safety Monitoring Board and device manufacturer, and regulatory filings with US FDA.

Clinical laboratory responsibilities included management of GCLP laboratory (four technicians) for sample processing, shipment and documentation, monitoring of clinical safety laboratories with nurse coordinator, coordination of HIV infection status monitoring in a blinded manner, and coordination of humoral assays for binding and neutralizing antibody activity.

Clinical research responsibilities included development and optimization of seven to ten color multiparametric flow cytometry assays to monitor cellular immune responses to candidate HIV-1 vaccines in humans and in mice, and development and optimization of humoral ELISAs to quantify antibody titer and kinetics in response to candidate vaccines.

2. 2005 – 2010, ADARC Vaccine Development Consortium, Bill and Melinda Gates Foundation Collaboration on AIDS Vaccine Discovery

Administrative Responsibilities Include establishment of subcontract agreements between multiple VDC institutions, coordination with Technology Transfer Offices to manage intellectual property in order to ensure Global Access of HIV-1 vaccines to the developing world, and financial oversight of a 24.7 million dollar five year budget.

Scientific Responsibilities include coordination of multiple investigators in order to ensure achievement of scientific milestones, and interaction with Gates Foundation and Consortium Core Facilities. Responsible for preclinical and clinical development of novel dendritic-cell targeted candidate HIV-1 vaccines and adjuvants, including regulatory, manufacturing, pre-clinical testing, clinical protocol design, and clinical trial conduct, and GCLP immunomonitoring.

3. Clinical Development of a Novel Monoclonal Antibody for Potential Prevention Against HIV-1

Responsible for design and oversight of Phase 1 and Phase 2a clinical trial protocol design and trial coordination, and oversight of clinical assays and data coordination.

4. Clinical Development of a Novel Glycolipid Compound as a Vaccine Adjuvant

Designing and conducting a Phase 1 clinical trial of a novel glycolipid compound that stimulates natural killer T cells to enhance humoral and cellular immunogenicity when co-administered with vaccines in mice. Responsible for oversight and coordination of all manufacturing, preclinical, and regulatory activities necessary to support advancement into clinical trials.

K. Support

Previous

Grant# 38648 (PI, Ho; Co-Investigator, Vasani) 07/01/06-06/30/11

Bill & Melinda Gates Foundation
Harnessing Dendritic Cells & Innate Immune Activation Signals to Guide HIV-1 Vaccine Development
Objective: To develop a vaccine that elicits durable cellular and humoral immunity to HIV-1 by targeting dendritic cells.

Grant# 50714 (PI, Ho; Co-Investigator, Vasani) 12/01/09-12/01/11

Bill & Melinda Gates Foundation
Development of Ibalizumab for HIV Prevention
Objective: To develop a novel monoclonal antibody with strong anti-HIV activity through blocking the CD4 receptor as prevention for SIV in macaques and HIV in humans.

Rockefeller University Clinical Scholars Program 5/01/02 – 12/31/04

- Protocol C001 (PI, Ho) 11/19/03 – 6/01/06
 IAVI –ADVAX Clinical Trial Agreement
 The overall objective of this project is to evaluate the safety and immunogenicity of ADVAX e/g + ADVAX p/n-t administered intramuscularly to healthy adult volunteers.
- Protocol C002 (PI, Ho) 12/13/04 – 7/31/07
 IAVI-ADMVA Clinical Trial Agreement
 Objective: To evaluate the safety and immunogenicity of ADMVA administered intramuscularly to healthy adult volunteers.
- Clinical Translational Pilot Grant Award (PI, Vasan) 12/22/06 – 7/01/07
 HIV DNA Vaccine Delivery by In Vivo Electroporation
 Objective: To evaluate the effect of route and vaccine schedule on immunogenicity of HIV-1 DNA vaccines delivered by in vivo electroporation in small animals to support clinical development.

L. Teaching/ Educational Responsibilities

- 1989 – 1992 Massachusetts Institute of Technology: Leader of MIT Society of Women Outreach Division. Organized several projects to expose inner city middle and high school girls to careers in math and science.
- 1994 – 1995 Massachusetts General Hospital: Timilty Middle School Science Project Mentor. Mentored an eighth grade students to organize, research, and present a science fair projects. Timilty Middle School Science Fair Judge.
- 1999 – 2000 Johns Hopkins Hospital: Organizer and presenter of departmental morbidity and mortality conferences.
- 2000 – 2001 National University of Singapore: Guest faculty advisor to a medical student humanitarian group.
- 2005 Course Organizer and Instructor, *Introduction to HIV Pathogenesis, Treatment, and Vaccine Development*, Aaron Diamond AIDS Research Center
- 2004 – 2010 Arthur Ashe Scholars Program: Host for international visiting scholars on the conduct of clinical trials of candidate HIV vaccines in healthy volunteers
- 2009 – 2011 Course Instructor, *Scientific Techniques*, Rockefeller University
- 2011 Course Instructor, *Global Health Emergencies*, Weil Cornell Medical College, New York Presbyterian Hospital

M. Prior Research

- 1990 Department of Geriatrics, Beth Israel Hospital, Boston: Researched efficacy of P³²-NMR spectroscopy in evaluating effects of starvation on fat content in rats.
- 1991 Ethicon, Inc., New Jersey: Designed instrumentation to aid in intracorporeal laparoscopic suturing and developed and tested prototype.
- 1991 - 1992 MIT Department of Mechanical Engineering, Boston: Researched mechanical

properties of surgical and optical instrumentation in laparoscopy and arthroscopy and proposed areas for technical improvement.

- 1993 Department of Infectious Diseases, Children's Hospital, Boston: Developed an algorithmic program and database using Visual Basic and C++ to evaluate potential spread of nosocomial infections in hospitals in developing nations and generate recommendations for improvement.
- 1994 - 1995 Reproductive Endocrine Unit, Massachusetts General Hospital, Boston: Studied effects of galanin, a hypothalamic peptide, on gonadotropin secretion from rat pituitary cells. Performed a molecular search for an autosomal recessive gene for Kallman's syndrome.
- 2000 - 2001 Communicable Disease Centre, Singapore: Conducted a study to assess patterns of tuberculosis infection among HIV-infected patients in Singapore, and generate diagnostic recommendations for national healthcare providers.
- 2002 – 2004 Aaron Diamond AIDS Research Center/ Rockefeller University, New York: Co-Investigator on several clinical research protocols to determine the impact of Initiating antiretroviral therapy during acute and early HIV-1 infection on immune preservation, viral evolution and viral drug resistance.

Completed clinical research protocols, Rockefeller University Hospital:

DHO-519 A Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Study to Evaluate the Safety and Immunogenicity of a Clade C DNA Vaccine ADVAX e/g + ADVAX p/n-t (ADVAX) Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers

DHO-0549 A Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Study to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) expressing HIV-1 Clade C env/gag-pol and nef-tat fusion genes (ADMVA) Vaccine Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers

DHO-0614 Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/n-t, by Ichor TriGrid™ *in vivo* Electroporation to HIV-Uninfected, Healthy Volunteers

MMA-283 Virologic and Immunologic Monitoring of HIV-1 Infected Subjects After Withdrawal of Antiretroviral Therapy

MMA-340 Transmission and Viral Dynamics of Drug Resistant HIV-1

MMA-377 A Phase I/II, Open-label Study to Evaluate the Ability of Combination Therapy with ABT 378/ritonavir (Kaletra), lamivudine (Epivir), efavirenz (Sustiva), and tenofovir (Tenofovir DF) to Completely Suppress Viral Replication in Subjects Infected with HIV-1

MMA-476 A probe study to evaluate HIV-1-specific cell mediated immune responses in HIV-1 infected patients treated with potent antiretroviral therapy during acute or recent infection

MMA-465 An Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

- MPO-500 Gastrointestinal lymphatic tissue sampling to determine active HIV-1 replication in subjects infected with HIV-1
- MMA-509 Acute Infection and Early Disease Research Program (AIEDRP) CORE01 Database Protocol
- MMA-520 A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12 and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated during Acute and Early HIV-1 Infection
- MMA-523 A Randomized Phase II Study of the Safety, Immunologic and Virologic Effects of Cyclosporine A in conjunction with Trizivir and Tenofovir DF versus Trizivir and Tenofovir DF alone during Primary HIV-1 Infection

N. Extramural Professional Activities

- 1997 Association Salvadoreña Pro Salud Rural (ASAPROSAR), El Salvador: Worked with a non-governmental organization focusing on preventative and primary health in women and children. Ran local medical clinics, conducted vaccination and pap smear campaigns, and educated community health workers in basic topics in preventative medicine in rural El Salvador. In addition, helped analyze and optimize resource utilization in various programs within the organization.
- 1999 UNICEF, Mumbai, India: Collaborated with municipal health officers and regional UNICEF officers to develop and assess survey tool to assess the “mother and child friendliness” of various regional hospitals. Worked with regional municipal office to observe polio vaccination program.
- 2001 National University of Singapore Medical School, Singapore: Organized and led a medical task force to work with the Indonesian Ministry of Health to conduct a health needs assessment in a rural village in Bintan, Indonesia. Simultaneously developed and implemented a maternal and school health education program for the same area. Provided medical services in the village clinic.
- 2006 Tuberculosis Research Center, Chennai, India: Invited Lecturer, *Clinical Development of HIV-1 Vaccines at the Aaron Diamond AIDS Research Center*
- 2008 University of Medicine and Dentistry of New Jersey, Department of Pathology: Invited Lecturer, *Obstacles and Current Approaches to HIV-1 Vaccine Development at the Aaron Diamond AIDS Research Center*
- 2008 Rockefeller University, Seminars in Clinical Investigation: Invited Lecturer, *Novel Approaches to Developing DNA-Based HIV-1 Vaccines*
- 2009- Present Scientific Advisor, Robert Mapplethorpe Foundation: Advise on funding allocation on grants supporting HIV/AIDS research, care and treatment

O. Bibliography

Publications

S. Vasan, A. Hurley, S.J. Schlesinger, D. Hannaman, D.F. Gardiner, D.P. Dugin, M.M. Boente-Carrera, R.M. Vittorino, M. Caskey, J. Andersen, Y. Huang, J. Cox, T. Tarragona, D.K. Gill, H. Cheeseman, L. Clark, L. Dally, C. Smith, C. Schmidt, H. Park, J. Kopycinski, J. Gilmour, P. Fast, R. Bernard, D.D. Ho. [In vivo electroporation enhances the immunogenicity an HIV-1 DNA vaccine candidate in healthy volunteers.](#) PLoS One. 2011;6(5):e19252

H. Hara, T. Hironaka, M. Inoue, A. Iida, T. Shu, M. Hasegawa, Y. Nagai, A. Falsey, L. Lopalco, A. Kamali, O. Anzala, E. Sanders, E. Karita, L. Mwananyanda, **S. Vasan**, A. Lombardo, C. Park, E. Sayeed, M. Krebs, E. Cormier, J. Ackland, M.A. Price, J.L. Excler. [Sendai virus-specific neutralizing antibody prevalence in different geographical populations: implications for AIDS vaccine development with Sendai virus vectors.](#) Human Vaccines, 2011, 7(6):

K. Dolter, C. Evans, B. Ellefsen, J. Song, M. Boente-Carrera, R. Vittorino, T. Rosenberg, D. Hannaman, **S. Vasan**. [Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.](#) Vaccine, 2011, Jan 17;29(4):795-803.

N. Padte, X. Li, M. Tsuji, **S. Vasan**. [Clinical Development of a Novel CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant.](#) Clinical Immunology, 2010, Dec 23.

X. Li, M. Fujio, D. Wu, **S. Vasan**, C. Wong, D. D. Ho, M. Tsuji. [Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.](#) Proceedings of the National Academy of Sciences, 2010. 107(29):13010-13015.

S. Vasan, S.J. Schlesinger, Y. Huang, A. Hurley, A. Lombardo, Z. Chen, S. Than, P. Adesanya, C. Bunce, M. Boaz, R. Boyle, E. Sayeed, L. Clark, D. Dugin, C. Schmidt, Y. Song, L. Seamons, L. Dally, M. Ho, C. Smith, M. Markowitz, J. Cox, D.K. Gill, J. Gilmour, M. C. Keefer, P. Fast, D. D. Ho. [Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-based Clade C/B' HIV-1 Candidate Vaccine](#) PLOS One, 2010, 5(1) e8617, p1-7.

S. Vasan, S. J. Schlesinger, Z. Chen, A. Hurley, A. Lombardo, S. Than, P. Adesanya, C. Bunce, M. Boaz, R. Boyle, E. Sayeed, L. Clark, D. Dugin, M. Boente-Carrera, C. Schmidt, Q. Fang, L. Ba, Y. Huang, G.J. Zaharatos, D.F. Gardiner, M. Caskey, L. Seamons, M. Ho L. Dally, C. Smith, J. Cox, D.K. Gill, J. Gilmour, M.C. Keefer, P. Fast, D. D. Ho. [Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine](#) PLOS One, 2010, 5(1) e8816, p1-7.

S. Vasan, M. Tsuji. [A double-edged sword: The role of NKT cells in malaria and HIV infection and immunity](#) Seminars in Immunology 2009, Dec 3.

S. Vasan, M. Poles, A. Horowitz, E. Siladji, M. Markowitz, M. Tsuji. [Percentage and function of NKT cells, a potential anti-HIV effector cell, are preserved by beginning HAART during acute HIV-1 infection.](#) International Immunology, 2007, 19(8):943-51.

S. Vasan, S. J. Schlesinger, G. Arrode. [T-Cell Immune Responses to HIV-1](#) Frontiers in Bioscience, 2007 Jan 1;12:2330-43.

S. Mehandru, T. Wrin, J. Galovich, G. Stiegler, B. Veclar, A. Hurley, C. Hogan, **S. Vasan**, H. Katinger, C. Petropoulos, M. Markowitz. [Neutralization Profiles of Newly Transmitted Human](#)

Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10. *Journal of Virology.* 2004, 78(24): 14309-14042.

Thesis Publications

S. Vasan Lack of effect of galanin on LH, FSH and free alpha subunit secretion from perfused male rat anterior pituitary cells. Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Doctor of Medicine Research Thesis. 1997.

S. Vasan Endoscopic surgery: An assessment of laparoscopic and arthroscopic technique and instrumentation. Massachusetts Institute of Technology Department of Mechanical Engineering Undergraduate Thesis. 1992.

Abstracts

S. Vasan, M. Boente-Carrera, J. McManus, N. Padte, A. Gettie, B. F. Grasperge, N. Patterson, C. Andrews, T. Richie, M. Tsuji. A Novel Glycolipid Adjuvant Significantly Boosts Cellular Immune Responses to an Adenoviral Vaccine in Non Human Primates. AIDS Vaccine 2011, Poster

X. Li, M. Fujio, M. Imamura, D. Wu, C.H.Wong, D.D. Ho, N. Padte, **S. Vasan**, M. Tsuji. A potent CD1d-binding NKT cell ligand as an adjuvant for vaccines against malaria and HIV. Keystone Symposia – NK and NKT Cell Biology 2011, Oral Symposium

S. Vasan, A. Hurley, D. Hannaman, J.Cox, J. Gilmour, D. Ho. DNA Vector/Electroporation Immunogenicity Trials. AIDS Vaccine 2010, Oral Symposium

H. Hara, T. Hironaka, M. Inoue, A. Iida, T. Shu, M. Hasegawa, Y. Nagai, A. Falsey, L. Lopalco, A. Kamali, O. Anzala, E. Sanders, E. Karita, L. Mwananyanda, **S. Vasan**, A. Lombardo, C. Park, E. Sayeed, M. Krebs, E. Cormier, J. Ackland, M.A. Price, J.L. Excler. Sendai virus-specific neutralizing antibody prevalence in different geographical populations: implications for AIDS vaccine development with Sendai virus vectors. AIDS Vaccine 2010 Conference. Poster

S. Vasan, A. Hurley, S.J. Schlesinger, D. Hannaman, D. Gardiner, D. Dugin, M. Boente-Carrera, R. Vittorino, M. Caskey, J. Andersen, Y. Huang, J. Cox, T. Tarragona, D. Gill, H. Cheeseman, L. Clark, L. Dally, C. Smith, C. Schmidt, H. Park, E. Sayeed, J. Gilmour, P. Fast, R. Bernard, D.D. Ho. In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers AIDS Vaccine 2009 Conference Oral Presentation #OA05-01

S. Vasan, A. Hurley, S.J. Schlesinger, D. Hannaman, D. Gardiner, D. Dugin, Y. Huang, J. Andersen, M. Caskey, C. Evans, K. Dolter, C. Schmidt, P. Fast, D.D. Ho. Safety and Tolerability of an Electroporation Procedure to Deliver ADVAX, a Clade C/B' Multigenic DNA-Based Candidate HIV-1 Vaccine, to Healthy Volunteers AIDS Vaccine 2008 Conference. Poster #13-20

C. Schmidt, S. Kochhar, J.L. Excler, C. Smith, A. McMichael, J. Bwayo, W. Jaoko, J. Weber, P. Kaleebu, B. Peters, G. Pantaleo, E. Vardas, A. Robinson, **S. Vasan**, M. Keefer, V.D. Ramanathan, R. Boyle, P. Fast. Cardiac safety/events in clinical trials with preventive HIV vaccine candidates based on Modified vaccinia Ankara (MVA) AIDS Vaccine 2008 Conference. Poster #13-22

S. Vasan, S.J. Schlesinger, Z. Chen, A. Hurley, S. Than, P. Adesanya, C. Bunce, M. Boaz, R. Boyle, E. Sayeed, D.F. Gardiner, G.J. Zaharatos, M. Caskey, Q. Fang, C. Schmidt, Y. Huang, L. Seamons, M. Ho, A. Lombardo, J. Gilmour, M. Keefer, P. Fast, D.D. Ho Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B' MVA-Based HIV-1 Candidate Vaccine, in Healthy Volunteers. AIDS Vaccine 2007 Conference. Oral Presentation #106822

G.J. Zaharatos, T.J. Rosenberg, D.F. Gardiner, **S. Vasan**, Y. Huang, F. Yu, M. Tsuji, F. Nimmerjahn, J.V. Ravetch, D.D. Ho. FcγRIIB blockade enhances humoral and cell-mediated immune responses to vaccine antigens. AIDS Vaccine 2007 Conference. Abstract #106995

S. Vasan, A. Hurley, D. Dugin, E. Londono, S.J. Schlesinger. Factors Influencing Participation and Retention of Healthy Volunteers in a Phase I trial of a Preventative Candidate HIV-1 Vaccine in New York City AIDS Vaccine 2006 Conference. Abstract # 484.00

S. Vasan, E. Siladji, C. Hogan, A. Hurley, M. Markowitz, M. Tsuji. NKT Cells are Preserved in Patients Beginning HAART During Acute Infection 11th Conference on Retroviral and Opportunistic Infections, 2004. Abstract #245

S. Mehandru, M. A. Poles, K. Tenner-Racz, P. Racz, A. Horowitz, C. Hogan, **S. Vasan**, A. Hurley, S. Schlesinger, D. Ho, M. Markowitz. Acute HIV Infection is Characterized by a Preferential Depletion of CD4+ T Cells from Effector Sites in the Colon Second International Workshop on Acute HIV-1 Infection, 2004. Abstract #P-09

C. Hogan, A. Hurley, **S. Vasan**, S. Mehandru, C. Chung, M. Markowitz. Treatment of Acute and Early HIV-1 Infection with Trizivir/ Efavirenz Second International Workshop on Acute HIV-1 Infection, 2004. Abstract # P-18

S. Mehandru, T. Wrin, J. Galovich, G. Stiegler, B. Veclar, A. Hurley, C. Hogan, **S. Vasan**, H. Katinger, C. Petropoulos, M. Markowitz. Neutralization Profiles by Monoclonal Antibodies 2F5, 2G12, and 4E10 of Plasma-Derived HIV-1 from 91 Newly Infected Individuals Second International Workshop on Acute HIV-1 Infection, 2004. Abstract #M-12

A. Shet, L. Rowe, C. Hogan, **S. Vasan**, S. Mehandru, A. Hurley, V. Simon, D. Boden, M. Markowitz. Prevalence of Transmitted Antiretroviral Resistance in Antiretroviral-Naive Patients with HIV-1 Primary Infection in 2003 Second International Workshop on Acute HIV-1 Infection, 2004. Abstract #T-12

V. Simon, C. Hogan, M. Louie, **S. Vasan**, N. Padte, J Vanderhoeven, K. Dawson, P. Balfe, M. Markowitz. Frequency of Transmitted Drug Resistance and Identification of Phylogenetic Clusters in a Homogenous Cohort of Newly Infected Individuals 10th Conference on Retroviral and Opportunistic Infections, 2003 Abstract #504

C. Hogan, M. Louie, **S. Vasan**, A. Hurley, A. Horowitz, C. Chung, A. Kim, M. DiMascio, A. Perelson, D. Ho, M. Markowitz. Assessing the Relative Efficacy of HAART Regimens Using Early Changes in Plasma Viremia 10th Conference on Retroviral and Opportunistic Infections, 2003. Abstract #573

S. Vasan, A. Earnest, YS Leo, CC Lee. Epidemiology Clinical Features, and Diagnosis of Tuberculosis in HIV Positive Patients in Singapore. 6th International Conference on AIDS in Asia and the Pacific, 2002.

Book Chapters

S. Vasan. Toxoplasma. In: Satoskar A, Simon G, Hotez P and Tsuji, M. eds. Medical Parasitology. Landes Bioscience, May 2008.